Cogent Biosciences reports Q2 2026 results, two bezuclastinib PDUFA dates aheadAug 10Quarterly updatebezuclastinibCogent Biosciences, Inc.
FDA grants orphan drug status to Inhibikase's IKT-001 for PAHJul 23Regulatory milestoneIKT-001Inhibikase Therapeutics
Novartis posts pelacarsen Phase 3 apheresis results, updates three drug labelsJul 17Weekly roundup, 8 itemscarbamazepineimatinib
GSK posts bepirovirsen QT results; registers Mo-Rez ovarian, endometrial Phase 3 trialsJul 10Weekly roundup, 6 itemsbepirovirsencamlipixant
Sign inSign in